Raymond James Financial Services Advisors’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $788K | Sell |
38,363
-58
| -0.2% | -$1.19K | ﹤0.01% | 2315 |
|
|
2024
Q2 | $860K | Buy |
38,421
+878
| +2% | +$19.7K | ﹤0.01% | 2181 |
|
|
2024
Q1 | $1.03M | Buy |
37,543
+1,318
| +4% | +$36.3K | ﹤0.01% | 2037 |
|
|
2023
Q4 | $1.1M | Buy |
36,225
+4,255
| +13% | +$130K | ﹤0.01% | 1915 |
|
|
2023
Q3 | $1.01M | Buy |
31,970
+5,574
| +21% | +$176K | ﹤0.01% | 1894 |
|
|
2023
Q2 | $1.08M | Buy |
26,396
+2,304
| +10% | +$94K | ﹤0.01% | 1883 |
|
|
2023
Q1 | $898K | Buy |
24,092
+862
| +4% | +$32.1K | ﹤0.01% | 1969 |
|
|
2022
Q4 | $810K | Sell |
23,230
-2,453
| -10% | -$85.6K | ﹤0.01% | 1978 |
|
|
2022
Q3 | $1.44M | Sell |
25,683
-37
| -0.1% | -$2.07K | ﹤0.01% | 1612 |
|
|
2022
Q2 | $1.33M | Sell |
25,720
-461
| -2% | -$23.9K | ﹤0.01% | 1669 |
|
|
2022
Q1 | $1.9M | Sell |
26,181
-11,649
| -31% | -$847K | ﹤0.01% | 1529 |
|
|
2021
Q4 | $4.47M | Buy |
37,830
+2,821
| +8% | +$334K | 0.01% | 1065 |
|
|
2021
Q3 | $4.7M | Buy |
35,009
+373
| +1% | +$50K | 0.01% | 1010 |
|
|
2021
Q2 | $5.61M | Sell |
34,636
-2,096
| -6% | -$339K | 0.01% | 913 |
|
|
2021
Q1 | $2.95M | Buy |
36,732
+12,791
| +53% | +$1.03M | 0.01% | 1181 |
|
|
2020
Q4 | $1.3M | Buy |
23,941
+8,408
| +54% | +$457K | ﹤0.01% | 1546 |
|
|
2020
Q3 | $309K | Sell |
15,533
-57,820
| -79% | -$1.15M | ﹤0.01% | 2256 |
|
|
2020
Q2 | $1.54M | Buy |
73,353
+62,527
| +578% | +$1.31M | ﹤0.01% | 1233 |
|
|
2020
Q1 | $132K | Sell |
10,826
-1,914
| -15% | -$23.3K | ﹤0.01% | 2173 |
|
|
2019
Q4 | $187K | Buy |
+12,740
| New | +$187K | ﹤0.01% | 2590 |
|